ITIF-保持美国生物制药的领导地位：为什么小型、研究密集型公司在美国创新生态系统中很重要（英）-2023.8-17页_890kb

Summary

US Dominance in Small Biopharma Firms

• The United States hosts 85% of the world's small, research-intensive (SRI) biopharma firms, with 193 such firms globally in 2021.
• U.S. firms account for 91% of all SRI biopharma firms in America and a significant portion of global SRI firms (85%) among the top 2,500 R&D investors.

Contributions to Innovation

• U.S. SRI biopharma firms invest heavily in R&D, contributing $25.3 billion in 2021, which is 18% of domestic biopharma R&D spending.
• They spend an average of $712,258 per employee on R&D in 2021, nearly double the global average and more than larger firms.
• These firms are critical for drug development, accounting for a majority of new molecular entities and driving biopharma competitiveness.

Policy Recommendations

• Congress should pass the American Innovation and Jobs Act to expand R&D tax credits, extend payroll tax offsets, and reform tax code provisions.
• Key changes include doubling the R&D tax credit limit, increasing gross receipts for credits, and allowing passive investors to claim net operating losses and credits.
• Repeal the Tax Cuts and Jobs Act's restriction on expensing R&D and amend sections 469 and 382 to ease funding constraints for these firms.